Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis: The J2J Multicentre Study.
Osty M, Altwegg R, Serrero M, Benezech A, Lecomte A, Cadiot G, Vuitton L, Wampach A, Nancey S, Buisson A, le Berre C, Rouillon C, Gilletta C, Goutorbe F, Fumery M, Hammoudi N, Caillo L, Vidon M, Arab N, Sickersen G, Cavicchi M, Vieujean S, Charkaoui M, Richard N, Wils P, Caron B, Amiot A, Nuzzo A, Laharie D, Kirchgesner J, Uzzan M; GETAID‐J2J group.
Osty M, et al. Among authors: caillo l.
Aliment Pharmacol Ther. 2025 Aug;62(4):430-439. doi: 10.1111/apt.70199. Epub 2025 May 22.
Aliment Pharmacol Ther. 2025.
PMID: 40400411
Free PMC article.